Physicians' Academy for Cardiovascular Education

New evidence in the treatment of hyperphosphatemia

Slides (presentation) - Feb. 22, 2012

New evidence in the treatment of hyperphosphatemia
 

Presentation prepared by
Prof Mario Gennaro Cozzolino
University of Milan
Italy

Presented at PACE Renal Master Class in Madrid, February 17-18, 2012


View presentation


Contempory issues in management
THE LINK BETWEEN BONE AND CARDIOVASCULAR DISEASE: THE CENTRAL ROLE OF PHOSPHATE
Avoid Calcium………..
Optimizing the Treatment of Hyperphosphatemia in Experimental Uremia
Consequences of Hyperphosphatemia on Parathyroid Function
Regulation of PTH mRNA Stability by Lanthanum Carbonate in CKD
Phosphate Regulation of Vascular Smooth Muscle Cell Calcification
Effect of PFA on Ca deposition in VSMCs
Effect of Lanthanum on Ca deposition in VSMCs
Calciphylaxis Responsive to Lanthanum Carbonate
Optimizing the Treatment of Hyperphosphatemia in CKD
Lanthanum carbonate reduces serum phosphate levels in CKD 3/4: Randomized multicentre trial
25D and 1,25D Levels Are not Affected by Lanthanum Carbonate in CKD Patients
Optimizing the Treatment of Hyperphosphatemia in Dialysis
Efficacy of Lanthanum in Patients Converting From Other Treatments
Lanthanum Carbonate vs Sevelamer: Differential Effects on Renal Osteodystrophy
Clinical study conducted in CKD 5 dialysis patients
Trial design
Fixed dose titration
Change in serum phosphate from baseline during treatment periods
MAIN REMARKS
Avoid Calcium!
Avoid Calcium!
Avoid Calcium!
Avoid Calcium!
BONE-VASCULAR AXIS: THE ROLE OF PHOSPHATE

Share this page with your colleagues and friends: